Ipsen has worked in close relation with the US Food and Drug Administration to maintain product supply as the product is a medical necessity.
Increlex’s active principle, IGF-1 is manufactured by Lonza Biologics at its Hopkinton facility, US.
The companies will work with FDA to supply Increlex to US patients, according to Ispen.
Increlex is prescribed to children who are very short for their age as their bodies do not make enough IGF-1.